| Identification | Back Directory | [Name]
SF0166 | [CAS]
1621332-91-9 | [Synonyms]
SF0166
3-Pyridinepropanoic acid, 6-(difluoromethoxy)-β-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-, (βS)- | [Molecular Formula]
C23H27F2N5O4 | [MOL File]
1621332-91-9.mol | [Molecular Weight]
475.5 |
| Hazard Information | Back Directory | [Uses]
Nesvategrast (SF0166) is a potent and selective αvβ3 antagonist with IC50 values of 0.6 nM, 8 nM, and 13 nM for αvβ3, αvβ6, and αvβ8, respectively. Nesvategrast inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 values of 7.6 pM to 76 nM. Nesvategrast decreases neovascularization in the oxygen-induced retinopathy mouse model[1]. | [in vivo]
Nesvategrast (Bilateral eye topical drip 5% Nesvategrast) inhibits retinal neovascularization in 129SVE newborn mice with oxygen-induced retinopathy (OIR) models[1]. | Animal Model: | Female 129SVE newborn mice with oxygen-induced retinopathy (OIR) models[1] | | Dosage: | 5% SF0166 | | Administration: | Bilateral eye topical drip 5% SF0166 | | Result: | Reduced new blood vessel formation. |
| [IC 50]
αvβ3: 0.6 nM (IC50); αvβ6: 8 nM (IC50); αvβ8: 13 nM (IC50) | [References]
[1] Askew BC, et, al. Ocular Distribution and Pharmacodynamics of SF0166, a Topically Administered αvβ3 Integrin Antagonist, for the Treatment of Retinal Diseases. J Pharmacol Exp Ther. 2018 Aug;366(2):244-250. DOI:10.1124/jpet.118.248427 |
|
|